Disc Medicine to Present Key Clinical Data at SOHO 2026
Event summary
- Disc Medicine will present initial Phase 2 data for DISC-3405 in polycythemia vera at SOHO 2026.
- Oral presentation of RESTORE-PV trial data scheduled for September 10, 2026.
- Additional myelofibrosis data for DISC-0974 to be presented.
- Presentations cover safety, efficacy, and patient-reported outcomes.
The big picture
Disc Medicine's presentations at SOHO 2026 highlight its focus on addressing unmet needs in hematologic diseases. The company is positioning itself as a key player in myeloproliferative neoplasms, with both DISC-3405 and DISC-0974 targeting distinct but related conditions. Success in these trials could validate its approach to heme biosynthesis and iron homeostasis as a therapeutic pathway.
What we're watching
- Clinical Efficacy
- How initial RESTORE-PV data will position DISC-3405 against existing polycythemia vera treatments.
- Pipeline Progress
- Whether DISC-0974's anemia data in myelofibrosis accelerates its development timeline.
- Market Differentiation
- The pace at which Disc Medicine can establish its portfolio as a leader in myeloproliferative neoplasm therapies.
Related topics